Index

- Lasagna L, Mosteller F, von Felsinger JM, Beecher HK. *A study of the placebo response.* Am J Med 1954; 16: 770-779. 1
- Lasagna L, von Felsinger JM. *The volunteer subject in research.* Science 1954; 120: 359-361. 13
- Lasagna L. *The controlled clinical trial: Theory and practice.* J Chron Dis 1955; 1: 353-367. 19
- Lasagna L, Laties VG, Dohan JL. *Further studies on the "pharmacology" of placebo administration.* J Clin Invest 1958; 37: 533-537. 37
- Lasagna L. *Gripesmanship: A positive approach.* J Chron Dis 1959; 10: 459-468. 45
- Murphy J, Casey W, Lasagna L. *The effect of dosage regimen on the diuretic efficacy of chlorothiazide in human subjects.* J Pharmacol Exp Ther 1961; 134: 286-290. 57
- Lasagna L. *A matter of perspective.* J Chron Dis 1962; 15: 3-5. 65
- Lasagna L. *The diseases drugs cause.* Perspect Biol Med 1964; 714: 457-470. 71
- Lasagna L. *Clinical Pharmacology: Present status and future development.* Science 1966; 152: 388-391. 87
- Lasagna L. *The clinical pharmacologist as a servant of society.* Can Med Assoc J 1967; 97: 109-113. 93
- Epstein LC, Lasagna L. *Obtaining informed consent: Form or substance.* Arch Intern Med 1969; 123: 682-688. 101

- Lasagna L. *The pharmaceutical revolution: Its impact on science and society.* Science 1969; 166: 1227-1233. 111
- Stolley PD, Lasagna L. *Prescribing patterns of physicians.* J Chron Dis 1969; 22: 395-405. 121
- Lasagna L. *Drug evaluation problems in academic and other contexts.* Ann NY Acad Sci 1970; 169: 503-508. 135
- Lasagna L. *Fault and default.* N Engl J Med 1973; 289: 267-268. 143
- Lasagna L. *A plea for the "naturalistic" study of medicines.* Eur J Clin Pharmacol 1974; 7: 153-154. 147
- Joubert P, Rivera-Calimlim L, Lasagna L. *The normal volunteer in clinical investigation: How rigid should selection criteria be?* Clin Pharmacol Ther 1975; 17: 253-257. 151
- Joubert P, Lasagna L. *Patient package inserts. I. Nature, notions, and needs.* Clin Pharmacol Ther 1975; 18: 507-513. 159
- Joubert P, Lasagna L. *Patient package inserts. II. Toward a rational patient package insert.* Clin Pharmacol Ther 1975; 18: 663-669. 169
- Karch FE, Lasagna L. *Toward the operational identification of adverse drug reactions.* Clin Pharmacol Ther 1977; 21: 247-254. 179
- Hassar M, Pocelinko R, Weintraub M, Nelson D, Thomas G, Lasagna L. *Free-living volunteer's motivation and attitudes toward pharmacologic studies in man.* Clin Pharmacol Ther 1977; 21: 515-519. 189
- Lasagna L. *The development and regulation of new medications.* Science 1978; 200: 871-873. 197
- Lasagna L. *Placebos and controlled trials under attack.* Eur J Clin Pharmacol 1979; 15: 373-374. 203
- Lasagna L. *Statistics: A new co-carcinogen.* Sciences 1980; 20 (5): 29-32. 207
- Lasagna L. *Historical controls*: *The practitioner's clinical trials.* N Engl J Med 1982; 307: 1339-1340. 211
- Lasagna L. *On assuring pharmacotherapeutic progress in the 21st century.* Br J Clin Pharmacol 1987; 23: 659-665. 215